Mineralys Deferred Long Term Liab vs Non Current Assets Total Analysis
| MLYS Stock | 13.11 0.59 4.71% |
Mineralys Therapeutics, financial indicator trend analysis is infinitely more than just investigating Mineralys Therapeutics, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mineralys Therapeutics, is a good investment. Please check the relationship between Mineralys Therapeutics, Deferred Long Term Liab and its Non Current Assets Total accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Deferred Long Term Liab vs Non Current Assets Total
Deferred Long Term Liab vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mineralys Therapeutics, Deferred Long Term Liab account and Non Current Assets Total. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Mineralys Therapeutics,'s Deferred Long Term Liab and Non Current Assets Total is 0.89. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Mineralys Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Mineralys Therapeutics,'s Deferred Long Term Liab and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Mineralys Therapeutics, Common are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Deferred Long Term Liab i.e., Mineralys Therapeutics,'s Deferred Long Term Liab and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.89 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Mineralys Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mineralys Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At this time, Mineralys Therapeutics,'s Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 769.5 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 130.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 27K | 1.7M | 1.9M | 2.0M | Depreciation And Amortization | 18.7M | 228.5K | 167.9K | 159.5K |
Mineralys Therapeutics, fundamental ratios Correlations
Click cells to compare fundamentals
Mineralys Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.